Merck & Co. (MRK) announced that it is terminating the development of osteoporosis candidate odanacatib due to an unacceptable safety profile, specifically an increased risk of stroke. It made the decision based on the findings from an independent analysis of the cardiovascular events. The company originally planned to file an NDA in the U.S. in 2015 despite the safety issues. Analysts projected peak sales of $1 billion by 2020.